APTHEarnings•globenewswire•
Applied Therapeutics Reports Second Quarter 2025 Financial Results
Sentiment:Negative (35)
Summary
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire